Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Resting-state EEG (RS-EEG) has emerged as a non-invasive, low-cost tool for Alzheimer’s disease (AD) diagnosis and ...

Converging evidence supports a key pathogenic role of the glymphatic system in the accumulation of pathological aggregates in ...

In an exclusive Q&A, a Biogen exec discussed the developer's quest to 'rapidly' bring its experimental SMA therapy salanersen ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of ...

Marcus Evans announces the PharmaPack Summit 2025, an invitation-only event dedicated to the leaders defining the future of pharmaceutical packaging.

The FDA has deemed Biogen's tofersen reasonably likely to produce a clinical benefit for patients.

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Revenue (GAAP) surged to $31.7 million, exceeding analysts’ expectations by 88.8% driven by strong ZURZUVAE growth. Net loss (GAAP) narrowed to $49.7 million. This revenue surge, exceeding analysts’ ...

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...